ONCOassist: A CE-approved clinical decision support app for Irish oncology professionals
Support app for oncology professionals
Mr Kevin Bambury, Commerical Lead, ONCOassist,, Dr Richard Bambury, Consultant Medical Oncologist and Chief Medical Officer, Cork University Hospital and ONCOassist, Cork and Mr Eoin O'Carroll, Engineer and Technical Manager, ONCOassist,
September 5, 2016
- Article
- Similar articles
-
The widespread availability of smartphones and their expanding capabilities have presented new opportunities for improving the delivery of healthcare. ONCOassist is an app designed to help oncology healthcare professionals in their day-to-day work. Its growing list of clinical decision support tools includes adjuvant chemotherapy calculators, AJCC staging information, CTCAE toxicity criteria, and prognostic and other useful clinical calculators. This information is designed to improve the efficiency of oncology clinicians. We now have 2,800 active users per month and Google Play and iTunes feedback has been very positive. For example 29 out of 30 gave ONCOassist 4 or 5 stars out of 5 on the Google Play Store.1 Ongoing development will include the addition of an adjuvant breast cancer tool and new prognostic algorithms. ONCOassist can be downloaded through Apple or Google AppStores and is free of charge for Irish users once signed up.
Introduction
Since the launch of the iPhone in 2007, usage of smartphones has grown year on year. It is estimated that by 2021, 6.3 billion people will own a smartphone, representing 70% of the world’s population.2 Just like PCs before them, the smartphone has now become a must have for those in the workplace. This has presented new opportunities for improving the delivery of healthcare, including that of increasing the efficiency and accuracy of oncology healthcare.
A study from Manhattan Research in 20123 reported that 87% of doctors now use smartphone apps on a daily basis when making medical decisions. More than 80% of these choose the iOS operating system (iPhone/iPad) as their preferred platform.
In 2011, while we were studying for our Master of Electronic Business in UCC, there was an emphasis placed on healthcare and the need for innovation in this space. With an ageing population stretching the capacity of the healthcare system and those working in it, the current system will be unable to manage without expanded capacity.3 Innovation in digital health and telehealth was seen as a way to help bridge this gap and free up healthcare professionals’ time.
After initial discussion with Dr Richard Bambury, who was a specialist registrar in medical oncology at the time, we identified a need for the development of a tool similar to Adjuvant! Online, but available in smartphone format. The specific use involved having the ability to access adjuvant calculators on a smartphone or tablet device, rather than having to find a computer, access the relevant website and print the result of the calculation before returning to the patient and showing it to them. This would result in clinicians saving time.
This initial scope of the project was later developed and improved based on interaction and feedback from the Irish and international oncology community.
Validation of unmet need
In order to validate the need in the market for an app like ONCOassist, we did initial research into the number of oncology professionals globally. We also reviewed the number of other oncology-related apps on the market.
We estimated that there was a total of 100,000 oncologists in the world, ASCO (American Society of Clinical Oncology) membership was 35,000.4 Further research has shown us that the breakdown of medical oncologists in the EU5 is estimated as per Table 1. Although this could be considered a relatively small market compared to other products, we felt that the market need and opportunity was sufficient enough to warrant further development.
(click to enlarge)
We also identified that, although apps like Epocrates and QxMD were on the market, they did not cater specifically for the needs of oncology healthcare professionals. We measured the popularity of these apps by examining AppStore ratings and by discussions with their users.
We carried out an initial survey to get direct feedback from Irish oncology professionals which confirmed the need among oncology healthcare professionals for a smartphone decision support calculator to help with decision-making. A total of 18 oncology professionals took part and the result of the survey showed an overwhelming positive response to the need for validated decision aids to help with adjuvant decision support. Only one of the 18 oncology professionals (5.6%) answered no to the query on whether a decision support tool with statistical information (eg. web-based tools) would help in making decisions.
We also found that the overwhelming majority of Irish oncology professionals were iPhone users in comparison to Android users (28 of 30 answering this question were iPhone users, two Android users). This reflected the global trend at the time.
Initial beta development phase and pilots
Based on this initial background research we decided there was adequate interest to continue to develop ONCOassist. We therefore decided to go ahead and build an alpha version for early market testing. We developed this for the iOS platform only, based on our initial market research.
We were accepted to the Ignite Business incubator programme in UCC where we planned to develop a beta version of ONCOassist. After a competitive application and interview process we were one of seven teams accepted to the Healthbox Accelerator programme in London. This three-month programme chooses promising early-phase healthcare start-up companies and provides them with funding, mentorship and networking opportunities.
The initial version of ONCOassist contained some prognostic algorithms, adjuvant tools for lung cancer and gastrointestinal stromal tumour (GIST), and useful oncology formulas. The plan was to launch ONCOassist, collect user feedback and further develop the app based on this.
We launched initial pilots with oncology professionals in Ireland through Cancer Trials Ireland (then called ICORG) and in the UK through the Clatterbridge Cancer Centre. We worked with a student (Sinead Walsh) from the Master of Business Economics programme in UCC, to help with the set up and management of the pilot programme. ONCOassist was piloted by 48 oncology professionals and this was followed with a survey and interviews of pilot users. A total of 37 professionals downloaded ONCOassist and of these, 18 answered an anonymous survey comprising 23 questions. We also carried out five interviews.
This initial pilot confirmed the need for a tool like ONCOassist in oncology clinical practice, but also outlined the need for further features and tools to make it more useful to oncology professionals. This was confirmed by Sinead Walsh’s thesis: “The findings reveal that the app is in theory beneficial and the majority feel that they are ‘moderately informed’ regarding decision-making using the app. However, in order for it to be fully useful to the oncologists, the company needs to work on developing the app further to include a whole host of additional features that are used daily in the area of oncology.”6
Based on feedback from this survey, ONCOassist was further developed. By having a feedback tab prominently displayed in the app and by directly emailing those who downloaded the app we found the users who piloted ONCOassist were very forthcoming in giving feedback on how ONCOassist could be improved.
User-based development approach
Early on in development we decided to take a user-based approach to the development of ONCOassist, by regularly interviewing and surveying our userbase to drive innovation.
We followed a lean start-up approach, a derivative of the lean manufacturing model as developed by Steve Blank and popularised by Eric Reiss.
This approach focuses on the needs of the end user and encourages developers to create a feedback loop between the end user and the development team; it encourages a continual process of ‘build-measure-learn’.7 This minimises the likelihood of developing features that won’t be used and is now considered a best practice in the development of software products.
CE approval – classification as medical device
ONCOassist was one of the first apps in the world to be CE approved. This is the European equivalent of FDA approval and means that ONCOassist is classified as a medical device.
This classification and its ongoing management took a number of months to complete. The process involved input from a technical, clinical and regulatory perspective. It included the writing of a clinical evidence report which underpins all of the tools and content we have in the app.
Partnership with European Society of Medical Oncology
We began engaging with the European Society of Medical Oncology after an initial meeting at the ASCO Annual Congress in 2012. We were in regular contact with them and a product like ONCOassist had been requested by their members.
In September 2014, we were invited to attend the ESMO Annual Conference in Madrid, Spain to demonstrate ONCOassist in the ESMO members lounge over a three-day period. After the demo, users were asked to complete an anonymous survey which was then submitted to ESMO.
A total of 78 ESMO members were surveyed and the results were overwhelmingly positive. A total of 83% of those surveyed said ONCOassist would be ‘very useful’ or ‘extremely useful’ in their clinical practice (see Figure 1), while 59% said they would use it every day and 33% said they would use it once a week.
(click to enlarge)
